Quick Summary — SPOK scores higher on quality with 8.9/10 vs PRVA's 7.6/10. PRVA trades at $20.80 while SPOK trades at $10.95. Both analyzed daily using SEC EDGAR data across 13 institutional models.
SPOK scores higher with a 8.9/10 quality rating vs PRVA's 7.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $20.80, PRVA trades +32.0% above its Bayesian DCF fair value of $14.14, while SPOK at $10.95 trades +26.0% above its estimate of $8.11. PRVA shows a wider gap between price and intrinsic value.
PRVA earns a Quality of Company score of 7.6/10 compared to SPOK's 8.9/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
PRVA carries a SAFE value trap risk (18/100) while SPOK shows SAFE risk (19/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both PRVA and SPOK operate in Health Information Services, which has 46 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare PRVA vs SPOK differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.